JP2021137024A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021137024A5 JP2021137024A5 JP2021095192A JP2021095192A JP2021137024A5 JP 2021137024 A5 JP2021137024 A5 JP 2021137024A5 JP 2021095192 A JP2021095192 A JP 2021095192A JP 2021095192 A JP2021095192 A JP 2021095192A JP 2021137024 A5 JP2021137024 A5 JP 2021137024A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- antibody
- engineered
- acid molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023119583A JP7717762B2 (ja) | 2015-02-06 | 2023-07-24 | 治療免疫細胞の有効性を改良するための方法 |
| JP2023119584A JP7719128B2 (ja) | 2015-02-06 | 2023-07-24 | 治療免疫細胞の有効性を改良するための方法 |
| JP2025124172A JP2025169264A (ja) | 2015-02-06 | 2025-07-24 | 治療免疫細胞の有効性を改良するための方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562112765P | 2015-02-06 | 2015-02-06 | |
| US62/112,765 | 2015-02-06 | ||
| US201562130970P | 2015-03-10 | 2015-03-10 | |
| US62/130,970 | 2015-03-10 | ||
| JP2017541243A JP6895380B2 (ja) | 2015-02-06 | 2016-02-05 | 治療免疫細胞の有効性を改良するための方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541243A Division JP6895380B2 (ja) | 2015-02-06 | 2016-02-05 | 治療免疫細胞の有効性を改良するための方法 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023119583A Division JP7717762B2 (ja) | 2015-02-06 | 2023-07-24 | 治療免疫細胞の有効性を改良するための方法 |
| JP2023119584A Division JP7719128B2 (ja) | 2015-02-06 | 2023-07-24 | 治療免疫細胞の有効性を改良するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021137024A JP2021137024A (ja) | 2021-09-16 |
| JP2021137024A5 true JP2021137024A5 (enExample) | 2022-06-02 |
| JP7320560B2 JP7320560B2 (ja) | 2023-08-03 |
Family
ID=56564429
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541243A Active JP6895380B2 (ja) | 2015-02-06 | 2016-02-05 | 治療免疫細胞の有効性を改良するための方法 |
| JP2021095192A Active JP7320560B2 (ja) | 2015-02-06 | 2021-06-07 | 治療免疫細胞の有効性を改良するための方法 |
| JP2023119583A Active JP7717762B2 (ja) | 2015-02-06 | 2023-07-24 | 治療免疫細胞の有効性を改良するための方法 |
| JP2023119584A Active JP7719128B2 (ja) | 2015-02-06 | 2023-07-24 | 治療免疫細胞の有効性を改良するための方法 |
| JP2025124172A Pending JP2025169264A (ja) | 2015-02-06 | 2025-07-24 | 治療免疫細胞の有効性を改良するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541243A Active JP6895380B2 (ja) | 2015-02-06 | 2016-02-05 | 治療免疫細胞の有効性を改良するための方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023119583A Active JP7717762B2 (ja) | 2015-02-06 | 2023-07-24 | 治療免疫細胞の有効性を改良するための方法 |
| JP2023119584A Active JP7719128B2 (ja) | 2015-02-06 | 2023-07-24 | 治療免疫細胞の有効性を改良するための方法 |
| JP2025124172A Pending JP2025169264A (ja) | 2015-02-06 | 2025-07-24 | 治療免疫細胞の有効性を改良するための方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US10765699B2 (enExample) |
| EP (2) | EP4134430A1 (enExample) |
| JP (5) | JP6895380B2 (enExample) |
| KR (2) | KR20250022235A (enExample) |
| CN (4) | CN113713091A (enExample) |
| AU (3) | AU2016216149B2 (enExample) |
| CA (1) | CA2975851A1 (enExample) |
| DK (1) | DK3253865T3 (enExample) |
| ES (1) | ES2926384T3 (enExample) |
| HR (1) | HRP20220890T1 (enExample) |
| HU (1) | HUE059662T2 (enExample) |
| LT (1) | LT3253865T (enExample) |
| PL (1) | PL3253865T3 (enExample) |
| PT (1) | PT3253865T (enExample) |
| RS (1) | RS63574B1 (enExample) |
| SG (2) | SG10201913124RA (enExample) |
| SI (1) | SI3253865T1 (enExample) |
| SM (1) | SMT202200353T1 (enExample) |
| WO (1) | WO2016126213A1 (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210014210A (ko) | 2014-05-15 | 2021-02-08 | 내셔널 유니버시티 오브 싱가포르 | 변형된 천연 살해 세포 및 그의 용도 |
| CN113713091A (zh) | 2015-02-06 | 2021-11-30 | 新加坡国立大学 | 工程免疫细胞及其用途和生产方法 |
| KR102632082B1 (ko) | 2015-02-27 | 2024-02-02 | 아이셀 진 테라퓨틱스 엘엘씨 | 혈액 악성종양을 표적으로 하는 키메라 항원 수용체(car), 조성물 및 이의 용도 |
| TWI781934B (zh) | 2016-05-27 | 2022-11-01 | 美商艾吉納斯公司 | 抗-tim-3抗體及其使用方法 |
| WO2018027036A1 (en) * | 2016-08-03 | 2018-02-08 | Dipersio John F | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors |
| CN109689693B (zh) * | 2016-11-03 | 2022-06-28 | 深圳华大生命科学研究院 | 提高基因编辑效率的方法和系统 |
| CN118581046A (zh) * | 2016-11-22 | 2024-09-03 | 新加坡国立大学 | 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体 |
| US11458169B2 (en) | 2017-02-22 | 2022-10-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | TIM3-binding chimeric antigen receptors |
| WO2018169922A2 (en) * | 2017-03-13 | 2018-09-20 | Kite Pharma, Inc. | Chimeric antigen receptors for melanoma and uses thereof |
| AU2018245749A1 (en) | 2017-03-27 | 2019-10-03 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| CA3056439A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| US11648269B2 (en) | 2017-08-10 | 2023-05-16 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof |
| WO2019077037A1 (en) * | 2017-10-18 | 2019-04-25 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | METHODS AND COMPOUNDS FOR ENHANCED IMMUNE CELL THERAPY |
| CA3078963A1 (en) | 2017-10-25 | 2019-05-02 | Actinium Pharmaceuticals, Inc. | Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies |
| US12365733B2 (en) | 2017-12-29 | 2025-07-22 | Cellectis | Method for improving production of car T cells |
| CN112566659A (zh) * | 2018-01-25 | 2021-03-26 | 库利南Mica公司 | Mica/b抗体和使用方法 |
| CN108314739B (zh) * | 2018-02-05 | 2020-07-14 | 深圳市默赛尔生物医学科技发展有限公司 | 多信号嵌合抗原受体及其表达基因、其修饰的nk细胞及应用 |
| SG11202007156QA (en) | 2018-02-09 | 2020-08-28 | Nat Univ Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| US20200392512A1 (en) * | 2018-02-26 | 2020-12-17 | Ablynx N.V. | Nucleotide sequences encoding peptide linkers |
| SG11202008976YA (en) * | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| SG11202010996QA (en) * | 2018-05-23 | 2020-12-30 | Nat Univ Singapore | Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies |
| US20200054675A1 (en) | 2018-06-01 | 2020-02-20 | Washington University | Suppression of cytokine release syndrome in chimeric antigen receptor cell therapy |
| US12486514B2 (en) | 2018-08-29 | 2025-12-02 | National University Of Singapore | Method to specifically stimulate survival and expansion of genetically-modified immune cells |
| CN109207430A (zh) * | 2018-09-25 | 2019-01-15 | 华东师范大学 | 一种嵌合抗原受体nk细胞及其制备方法和应用 |
| CN109266618B (zh) * | 2018-10-18 | 2021-04-23 | 赛元生物科技(杭州)有限公司 | 能够靶向肿瘤细胞的巨噬细胞及其制备方法 |
| KR20200049594A (ko) * | 2018-10-24 | 2020-05-08 | 주식회사 툴젠 | 조작된 면역 세포 |
| KR20210125978A (ko) | 2018-11-01 | 2021-10-19 | 그라셀 바이오테크놀로지스 (상하이) 컴퍼니, 리미티드 | T 세포 조작을 위한 조성물 및 방법 |
| WO2020102589A1 (en) | 2018-11-14 | 2020-05-22 | Medisix Therapeutics Pte Ltd. | Two-gene vectors for generating car-t cells and uses thereof |
| CN109652379B (zh) * | 2018-12-29 | 2022-08-16 | 博生吉医药科技(苏州)有限公司 | Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| IL288024B2 (en) | 2019-05-14 | 2025-12-01 | Provention Bio Inc | Methods and compositions for preventing type |
| BR112021026416A8 (pt) * | 2019-06-28 | 2022-06-28 | Cafa Therapeutics Ltd | Célula resistente à rejeição imune a transplante, e, métodos para impedir ou regular rejeição imune a transplante e para impedir ou regular o ataque de célula nk em células exógenas |
| GB201914611D0 (en) * | 2019-10-09 | 2019-11-20 | Autolus Ltd | Engineered immune cell |
| CN114746126A (zh) * | 2019-10-11 | 2022-07-12 | 小利兰·斯坦福大学理事会 | 用于可调节细胞定位的重组多肽 |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| CN118562007A (zh) * | 2019-12-19 | 2024-08-30 | 苏州方德门达新药开发有限公司 | 工程改造的t细胞、其制备及应用 |
| CN113088495B (zh) * | 2020-01-09 | 2024-08-16 | 苏州方德门达新药开发有限公司 | 工程改造的t细胞、其制备及应用 |
| BR112022016633A2 (pt) * | 2020-02-27 | 2022-12-13 | Novartis Ag | Métodos para produzir células que expressam receptor de antígeno quimérico |
| WO2021249462A1 (zh) * | 2020-06-11 | 2021-12-16 | 南京北恒生物科技有限公司 | 表达nk抑制性分子的工程化免疫细胞及其用途 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| EP4168438A4 (en) | 2020-06-22 | 2024-07-10 | Ramot at Tel-Aviv University Ltd. | Multi subunit protein modules, cells expressing same and uses thereof |
| CN112195155A (zh) * | 2020-08-11 | 2021-01-08 | 广东万海细胞生物科技有限公司 | 一种通用car-t细胞及其制备方法 |
| CN114525259B (zh) * | 2020-11-03 | 2025-02-14 | 南京北恒生物科技有限公司 | 靶向cd7的嵌合抗原受体及其用途 |
| CA3201499A1 (en) | 2020-11-13 | 2022-05-19 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
| AU2021401934A1 (en) * | 2020-12-14 | 2023-06-22 | Allogene Therapeutics, Inc. | Methods and reagents for characterizing car t cells for therapies |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| CN115786271B (zh) * | 2021-01-12 | 2025-07-22 | 上海雅科生物科技有限公司 | 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用 |
| CN114853900A (zh) * | 2021-02-03 | 2022-08-05 | 南京北恒生物科技有限公司 | 新型嵌合抗原受体及其用途 |
| CA3212398A1 (en) | 2021-03-17 | 2022-09-22 | Daniel Getts | Engineered chimeric fusion protein compositions and methods of use thereof |
| CA3218780A1 (en) | 2021-05-11 | 2022-11-17 | Daniel Getts | Methods and compositions for genomic integration |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| CN113416701B (zh) * | 2021-07-28 | 2023-05-09 | 新疆西部赛澳生物科技有限责任公司 | 一种nk细胞培养基及培养方法 |
| US20240335535A1 (en) * | 2021-07-30 | 2024-10-10 | St Phi Therapeutics Co., Ltd. | Universal t cell and appication thereof |
| EP4649093A2 (en) | 2023-01-12 | 2025-11-19 | National University of Singapore | Blockade of cd8 expression and chimeric antigen receptors for immunotherapy of t-cell and nk-cell malignancies |
| WO2024154122A1 (en) | 2023-01-18 | 2024-07-25 | Gilboa Therapeutics LTD | Immune cells expressing a complement receptor and uses thereof |
| WO2024236557A1 (en) | 2023-05-12 | 2024-11-21 | Gilboa Therapeutics LTD | Compositions comprising an fc domain for the treatment of medical conditions |
| CN116731205B (zh) * | 2023-05-19 | 2024-02-27 | 皖南医学院第一附属医院（皖南医学院弋矶山医院） | 一种表达TGFβRII和TIM3胞外区的免疫增强型融合蛋白及其应用 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
| CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| EP1015616A2 (en) * | 1997-09-19 | 2000-07-05 | Dana Farber Cancer Institute, Inc. | Intrabody-mediated control of immune reactions |
| WO2001029058A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US6699473B2 (en) | 2000-10-13 | 2004-03-02 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
| AU2002220265A1 (en) * | 2000-11-03 | 2002-05-15 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| WO2003051926A2 (en) | 2001-12-14 | 2003-06-26 | Friedrich-Alexander-Universitaet Erlangen-Nuernberg | Anti-cd7 immunotoxin as fusion protein |
| KR101420344B1 (ko) | 2003-07-02 | 2014-07-16 | 위니베르시따 디 제노바 | Ｐａｎ-ｋｉｒ2ｄｌ ｎｋ-수용체 항체 및 진단 및 치료에서의 그 사용 방법 |
| US20090191213A9 (en) | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
| WO2005017163A2 (en) | 2003-08-15 | 2005-02-24 | Imperial College Innovations Limited | Phenotypic knockout of cell-surface proteins |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| AU2004309373A1 (en) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Methods for identifying functional antibodies |
| DK2287195T3 (da) * | 2004-07-01 | 2019-08-19 | Innate Pharma | Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi |
| AU2005299353A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune, Llc | Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections |
| WO2006072625A2 (en) | 2005-01-06 | 2006-07-13 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
| US20070036773A1 (en) * | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| US7973136B2 (en) | 2005-10-06 | 2011-07-05 | Xencor, Inc. | Optimized anti-CD30 antibodies |
| DE112007000801T5 (de) * | 2006-03-28 | 2009-02-12 | Hampton University | Hadronen-Behandlungsplanung mit adäquater biologischer Gewichtung |
| MX338151B (es) | 2007-03-01 | 2016-04-05 | Symphogen As | Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico. |
| ES2424745T3 (es) | 2007-09-07 | 2013-10-08 | Agensys, Inc. | Anticuerpos y moléculas relacionadas que se unen a las proteínas 24P4C12 |
| CN101952317B (zh) * | 2008-01-24 | 2015-07-22 | 诺沃-诺迪斯克有限公司 | 人化抗-人nkg2a单克隆抗体 |
| US8580714B2 (en) | 2009-10-14 | 2013-11-12 | Janssen Biotech, Inc. | Methods of affinity maturing antibodies |
| US9273283B2 (en) * | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| MX2014010183A (es) | 2012-02-22 | 2015-03-20 | Univ Pennsylvania | Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer. |
| PL4289948T3 (pl) | 2012-05-25 | 2025-06-02 | The Regents Of The University Of California | Sposoby i kompozycje do modyfikacji kierowanego na rna docelowego dna i do nakierowanej na rna modulacji transkrypcji |
| HRP20250822T1 (hr) * | 2012-07-13 | 2025-09-26 | The Trustees Of The University Of Pennsylvania | UPRAVLJANJE TOKSIČNOŠĆU ZA PROTUTUMORSKO DJELOVANJE CAR-a |
| AU2013329186B2 (en) * | 2012-10-10 | 2019-02-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| KR101521224B1 (ko) * | 2012-12-20 | 2015-05-19 | 한양대학교 산학협력단 | T 세포 특이적인 인간화 단일조각항체 전달체 |
| SG11201502792TA (en) * | 2012-12-27 | 2015-05-28 | Aduro Biotech Inc | Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof |
| NZ711807A (en) * | 2013-02-06 | 2020-06-26 | Celgene Corp | Modified t lymphocytes having improved specificity |
| EP2961831B1 (en) | 2013-02-26 | 2020-06-10 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
| EP2968520B1 (en) | 2013-03-14 | 2021-05-12 | MacroGenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
| US9890393B2 (en) | 2013-05-29 | 2018-02-13 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system |
| SG11201603484PA (en) * | 2013-11-21 | 2016-05-30 | Ucl Business Plc | Cell |
| US10836998B2 (en) | 2014-02-14 | 2020-11-17 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| WO2016011210A2 (en) | 2014-07-15 | 2016-01-21 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| MX2017004603A (es) | 2014-10-07 | 2017-06-30 | Cellectis | Metodo para modular actividad de celulas inmunes inducidas por car. |
| AU2015339743C1 (en) | 2014-10-31 | 2021-04-22 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified T cells and uses thereof |
| PT3560953T (pt) * | 2014-12-24 | 2024-03-26 | Autolus Ltd | Célula |
| US11161907B2 (en) * | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| CN113713091A (zh) * | 2015-02-06 | 2021-11-30 | 新加坡国立大学 | 工程免疫细胞及其用途和生产方法 |
| KR102632082B1 (ko) | 2015-02-27 | 2024-02-02 | 아이셀 진 테라퓨틱스 엘엘씨 | 혈액 악성종양을 표적으로 하는 키메라 항원 수용체(car), 조성물 및 이의 용도 |
| AU2016228080B2 (en) * | 2015-03-02 | 2020-11-12 | Innovative Cellular Therapeutics Holdings, Ltd. | Reducing immune tolerance induced by PD-L1 |
| EP3310915A4 (en) | 2015-06-19 | 2019-04-10 | Massachusetts Institute of Technology | TUMOR IMMUNOTHERAPY |
| JP7245647B2 (ja) | 2015-07-15 | 2023-03-24 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法用の操作された細胞 |
| IL295616A (en) | 2015-07-31 | 2022-10-01 | Us Health | Adapted cells and treatment methods |
| BR112018006811A2 (en) | 2015-10-06 | 2018-10-16 | Regents Of The University Of Minnesota | therapeutic compounds and methods |
| WO2017112877A1 (en) | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| US11390658B2 (en) | 2016-06-06 | 2022-07-19 | St. Jude Children's Research Hospital | Anti-CD7 chimeric antigen receptor and method of use thereof |
| JP7114490B2 (ja) | 2016-06-24 | 2022-08-08 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| CA2937157A1 (en) | 2016-07-25 | 2018-01-25 | Ucl Business Ltd | Protein-based t-cell receptor knockdown |
| WO2018027036A1 (en) | 2016-08-03 | 2018-02-08 | Dipersio John F | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors |
| CN118581046A (zh) | 2016-11-22 | 2024-09-03 | 新加坡国立大学 | 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体 |
| GB201622044D0 (en) | 2016-12-22 | 2017-02-08 | Ucl Business Plc | T cell-targeted T cells |
| US12459975B2 (en) | 2017-01-10 | 2025-11-04 | The General Hospital Corporation | Modified T cells and methods of their use |
| US11648269B2 (en) | 2017-08-10 | 2023-05-16 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof |
| WO2020102589A1 (en) | 2018-11-14 | 2020-05-22 | Medisix Therapeutics Pte Ltd. | Two-gene vectors for generating car-t cells and uses thereof |
-
2016
- 2016-02-05 CN CN202111064400.5A patent/CN113713091A/zh active Pending
- 2016-02-05 PT PT167469220T patent/PT3253865T/pt unknown
- 2016-02-05 US US15/548,577 patent/US10765699B2/en active Active
- 2016-02-05 CN CN202210661143.1A patent/CN114891816B/zh active Active
- 2016-02-05 EP EP22180254.9A patent/EP4134430A1/en active Pending
- 2016-02-05 JP JP2017541243A patent/JP6895380B2/ja active Active
- 2016-02-05 KR KR1020257003185A patent/KR20250022235A/ko active Pending
- 2016-02-05 SG SG10201913124RA patent/SG10201913124RA/en unknown
- 2016-02-05 WO PCT/SG2016/050063 patent/WO2016126213A1/en not_active Ceased
- 2016-02-05 KR KR1020177024662A patent/KR102763121B1/ko active Active
- 2016-02-05 DK DK16746922.0T patent/DK3253865T3/da active
- 2016-02-05 EP EP16746922.0A patent/EP3253865B1/en active Active
- 2016-02-05 HU HUE16746922A patent/HUE059662T2/hu unknown
- 2016-02-05 CA CA2975851A patent/CA2975851A1/en active Pending
- 2016-02-05 LT LTEPPCT/SG2016/050063T patent/LT3253865T/lt unknown
- 2016-02-05 PL PL16746922.0T patent/PL3253865T3/pl unknown
- 2016-02-05 SG SG11201706236SA patent/SG11201706236SA/en unknown
- 2016-02-05 CN CN201680018962.7A patent/CN107709548B/zh active Active
- 2016-02-05 SI SI201631593T patent/SI3253865T1/sl unknown
- 2016-02-05 RS RS20220680A patent/RS63574B1/sr unknown
- 2016-02-05 CN CN202210667502.4A patent/CN115029362A/zh active Pending
- 2016-02-05 ES ES16746922T patent/ES2926384T3/es active Active
- 2016-02-05 HR HRP20220890TT patent/HRP20220890T1/hr unknown
- 2016-02-05 SM SM20220353T patent/SMT202200353T1/it unknown
- 2016-02-05 AU AU2016216149A patent/AU2016216149B2/en active Active
-
2020
- 2020-07-30 US US16/943,400 patent/US12404491B2/en active Active
-
2021
- 2021-06-07 JP JP2021095192A patent/JP7320560B2/ja active Active
-
2022
- 2022-06-29 AU AU2022204601A patent/AU2022204601B2/en active Active
- 2022-07-12 US US17/862,721 patent/US11679132B2/en active Active
- 2022-07-12 US US17/862,797 patent/US12404492B2/en active Active
-
2023
- 2023-07-24 JP JP2023119583A patent/JP7717762B2/ja active Active
- 2023-07-24 JP JP2023119584A patent/JP7719128B2/ja active Active
-
2025
- 2025-07-03 AU AU2025205077A patent/AU2025205077A1/en active Pending
- 2025-07-24 JP JP2025124172A patent/JP2025169264A/ja active Pending
- 2025-07-30 US US19/285,735 patent/US20250354119A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021137024A5 (enExample) | ||
| JP7719128B2 (ja) | 治療免疫細胞の有効性を改良するための方法 | |
| JP2023059873A5 (enExample) | ||
| JP2025065142A5 (enExample) | ||
| Geldres et al. | Chimeric antigen receptor-redirected T cells return to the bench | |
| IL264104B1 (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
| JP2019509764A (ja) | 初代細胞のためのトランスポゾンに基づく転移システム | |
| JPWO2021173995A5 (enExample) | ||
| JP2023541132A (ja) | 免疫細胞におけるアダプターの誘導性発現のための系 | |
| CN121311239A (zh) | 包含替代信号传导结构域的平行嵌合抗原受体（pCAR）及衔接子嵌合抗原受体及其使用方法 | |
| JPWO2021205172A5 (enExample) | ||
| US20260049118A1 (en) | Single-chain chimeric polypeptides and uses thereof | |
| JP2025524457A (ja) | 哺乳動物におけるキメラ抗原受容体介在性の免疫応答を刺激するための方法において使用するためのｃｄ１２３に対する標的化モジュール | |
| KR20250111218A (ko) | 혈액학적 암의 치료에 사용하기 위한 키트 | |
| HK40086170A (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| Debets et al. | TCR-Engineered T cells | |
| NZ734107B2 (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| JPWO2022243565A5 (enExample) |